[go: up one dir, main page]

WO2001075029A2 - Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide - Google Patents

Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide Download PDF

Info

Publication number
WO2001075029A2
WO2001075029A2 PCT/CN2001/000386 CN0100386W WO0175029A2 WO 2001075029 A2 WO2001075029 A2 WO 2001075029A2 CN 0100386 W CN0100386 W CN 0100386W WO 0175029 A2 WO0175029 A2 WO 0175029A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide
human
related factor
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/000386
Other languages
English (en)
Chinese (zh)
Other versions
WO2001075029A3 (fr
Inventor
Yumin Mao
Yi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to AU56059/01A priority Critical patent/AU5605901A/en
Publication of WO2001075029A2 publication Critical patent/WO2001075029A2/fr
Publication of WO2001075029A3 publication Critical patent/WO2001075029A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Definitions

  • the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention.
  • Variants of this polynucleotide can be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
  • 13 ⁇ 4 recombinant gene therapy vectors can be used to treat diseases caused by abnormal expression or activity of human NF-E2-related factor 11.
  • Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus, etc. can be used to transfer a polynucleotide encoding human NF-E 2 related factor 11 into a cell.
  • Methods for constructing recombinant viral vectors carrying a polynucleotide encoding human NF-E2 related factor 11 can be found in existing literature (Sambrook, et al.). Another recombinant encoding human NF-E2 related factor 11
  • the polynucleotide can be packaged into liposomes and transferred into cells.
  • the 0537el2 clone contains a full-length cDNA of 2690bp (as shown in Seq ID NO: 1), and a 303bp open reading frame (0RF) from 188bp to 490bp, encoding a new protein (such as Seq ID NO : Shown in 2).
  • This clone pBS-0537el2 and the encoded protein was named human NF-E2 related factor 11.
  • Example 2 Cloning of a gene encoding human NF-E2 related factor 11 by RT-PCR
  • Pr imerl 5,-TTCAAATCCCAGCTCTGCTACTCA -3, (SEQ ID NO: 3)
  • Primer2 is the 3 'end reverse sequence in SEQ ID NO: 1.
  • the probes used in this embodiment include two types: the first type of probes are oligonucleotide fragments that are completely the same as or complementary to the polynucleotide SEQ ID NO: 1 of the present invention; the second type of probes are partially related to the present invention
  • the polynucleotide SEQ ID NO: 1 is the same or complementary oligonucleotide fragment.
  • the dot blot method is used to fix the sample on the filter membrane. Under the high-intensity washing conditions, the first type of probe and the sample have the strongest hybridization specificity and are retained.
  • the sample membrane was placed in a plastic bag, and 3 to 10 mg of a prehybridization solution (10xDenhardf s; 6xSSC, 0.1 lrag / ml CT DM (calf thymus DM)) was added. After sealing the bag, shake at 68 ° C for 2 hours.
  • a prehybridization solution (10xDenhardf s; 6xSSC, 0.1 lrag / ml CT DM (calf thymus DM)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un nouveau polypeptide, un facteur humain 11 associé à NF-E2, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment de toutes sortes de tumeurs, des troubles du développement de l'embryon, des troubles du développement et de la croissance, des inflammations, des maladies immunitaires, de l'hémopathie et de l'infection par VIH. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour le facteur humain 11 associé à NF-E2.
PCT/CN2001/000386 2000-03-24 2001-03-23 Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide Ceased WO2001075029A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56059/01A AU5605901A (en) 2000-03-24 2001-03-23 A novel polypeptide, nf-e2-associated human factor 11 and the polynucleotide encoding the polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00115100.2 2000-03-24
CN 00115100 CN1315351A (zh) 2000-03-24 2000-03-24 一种新的多肽——人一种组织或发育阶段特异转录因子相关因子11和编码这种多肽的多核苷酸

Publications (2)

Publication Number Publication Date
WO2001075029A2 true WO2001075029A2 (fr) 2001-10-11
WO2001075029A3 WO2001075029A3 (fr) 2002-05-10

Family

ID=4584569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000386 Ceased WO2001075029A2 (fr) 2000-03-24 2001-03-23 Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide

Country Status (3)

Country Link
CN (1) CN1315351A (fr)
AU (1) AU5605901A (fr)
WO (1) WO2001075029A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990090A (en) * 1993-09-20 1999-11-23 The University Of Michigan Methods and compositions for treatment of diseases
JP4295831B2 (ja) * 1997-01-15 2009-07-15 ポラリス・グループ 改変された腫瘍壊死因子
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子ＮＦκＢ活性化阻害剤

Also Published As

Publication number Publication date
CN1315351A (zh) 2001-10-03
WO2001075029A3 (fr) 2002-05-10
AU5605901A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
WO2001083688A2 (fr) Nouveau polypeptide, sous-unite humaine 13 phosphatidylinositol-4-phosphate-5-kinase ii beta, et polynucleotide codant pour ce polypeptide
WO2001068689A1 (fr) Nouveau polypeptide, 1alpha sous-unite 13 humaine du facteur adaptatif de l'hypoxie, et polynucleotide codant pour ce polypeptide
WO2001083538A1 (fr) Nouveau polypeptide, proteine humaine 36 du gene k-ras, et polynucleotide codant pour ce polypeptide
WO2001068684A1 (fr) Nouveau polypeptide, protocadherine humaine 14, et polynucleotide codant pour ce polypeptide
WO2001075029A2 (fr) Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2001075023A2 (fr) Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase humaine 9, et polynucleotide codant pour ce polypeptide
WO2001087972A1 (fr) Nouveau polypeptide, proteine dpc4 humaine 9 du facteur d'inhibition de la croissance tumorale, et polynucleotide codant ce polypeptide
WO2001072801A1 (fr) Nouveau polypeptide, proteine ribosomale humaine s11 12, et polynucleotide codant pour ce polypeptide
WO2001068873A1 (fr) Nouveau polypeptide, molecule humaine d'adhesion intercellulaire 12, et polynucleotide codant pour ce polypeptide
WO2001070965A1 (fr) Nouveau polypeptide, facteur humain de regulation de la transcription 15, et polynucleotide codant pour ce polypeptide
WO2001055374A1 (fr) Nouveau polypeptide, sequence 71 de multirepetition de la leucine, et polynucleotide codant pour ce polypeptide
WO2001072807A1 (fr) Nouveau polypeptide, neuropeptide humain 11, et polynucleotide codant pour ce polypeptide
WO2001072790A1 (fr) Nouveau polypeptide, proteine humaine p40 12 de facteur l1, et polynucleotide codant pour ce polypeptide
WO2001079423A2 (fr) Nouveau polypeptide, proteine humaine bcr 10, et polynucleotide codant pour ce polypeptide
WO2001075024A2 (fr) Nouveau polypeptide, facteur humain 13 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2001074887A1 (fr) Nouveau polypeptide, proteine humaine 9 humsiah, et polynucleotide codant pour ce polypeptide
WO2001081393A1 (fr) Nouveau polypeptide, proteine kinase ysk1 humaine 20, et polynucleotide codant pour ce polypeptide
WO2002000698A1 (fr) Nouveau polypeptide, proteine humaine 12 de transport de l'acide phosphorique, et polynucleotide codant ce polypeptide
WO2001081392A1 (fr) Nouveau polypeptide, phosphoproteine nucleolaire humaine 13, et polynucleotide codant pour ce polypeptide
WO2001073008A1 (fr) Nouveau polypeptide, nucleoproteine humaine 13 associee aux tumeurs, et polynucleotide codant pour ce polypeptide
WO2001072813A1 (fr) Nouveau polypeptide, facteur humain 6-14 de couplage de l'atpase mitochondriale, et polynucleotide codant pour ce polypeptide
WO2001079433A2 (fr) Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 13, et polynucleotide codant pour ce polypeptide
WO2001081536A2 (fr) Nouveau polypeptide, proteine kinase ysk1 humaine 10, et polynucleotide codant pour ce polypeptide
WO2001064730A1 (fr) Nouveau polypeptide, 5-phosphatase humaine 18, et polynucleotide codant pour ce polypeptide
WO2001078755A2 (fr) Nouveau polypeptide, proteine humaine de mutation 9 de l'ataxie-telangiectasie, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP